[{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2||Matrix protein 2","graph1":"Neurology","graph2":"Phase IV","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Oregon Health and Science University \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2||NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2||NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2||NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2||NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2||NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2||NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"SHINKEI Therapeutics, Inc","sponsor":"Duke Clinical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SHINKEI Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHINKEI Therapeutics, Inc \/ Duke Clinical Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"SHINKEI Therapeutics, Inc \/ Duke Clinical Research Institute"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Amantadine Hydrochloride","moa":"Glutamate [NMDA] receptor | Matrix protein 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Extended Release","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Noblewell","sponsor":"Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Matrix protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Noblewell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noblewell \/ Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre","highestDevelopmentStatusID":"10","companyTruncated":"Noblewell \/ Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Matrix protein 2","graph1":"Neurology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Weill Medical College of Cornell University \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Matrix protein 2","graph1":"Neurology","graph2":"Phase III","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adamas Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adamas Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Matrix protein 2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Mantadix
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
